We are live on !
Find out more
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter Est. Return
+32.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,270.13%
10 Year Est. Return
+54,096.87%
AUM
$6.66B
AUM Growth
+$1.54B
(+30%)
Cap. Flow
+$235M
Cap. Flow % of AUM
Cap. Flow %
3.53%
Top 10 Holdings %
Top 10 Hldgs %
47.3%
Holding
121
New
27
Increased
30
Reduced
28
Closed
12
Avg Time Held
Equity + Options
1.3
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KARD
Kardigan Inc
KARD
|
+$190M |
| 2 |
Avalyn Pharma
AVLN
|
+$77.2M |
| 3 |
Tango Therapeutics
TNGX
|
+$63.5M |
| 4 |
Relay Therapeutics
RLAY
|
+$63.2M |
| 5 |
Biogen
BIIB
|
+$52.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$209M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$85.9M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
+$37.6M |
| 4 |
Dyne Therapeutics
DYN
|
+$36.8M |
| 5 |
Abivax
ABVX
|
+$28.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.3% |
| 2 | Miscellaneous | 3.58% |
| 3 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Adaptive Biotechnologies
ADPT
$4.42B
| $26.1M | 0.39% |
1,217,325
+1,064,825
| +698% | +$16.3M |
2026 Q1
1 quarter
|
|
52
SAB Biotherapeutics
SABS
$280M
| $25.8M | 0.39% |
6,627,501
+195,758
| +3% | +$728K |
2025 Q4
2 quarters
|
|
53
Danaher
DHR
$163B
| $24.8M | 0.37% |
+130,000
| New | +$23.6M |
2026 Q2
0 quarters
|
|
54
Tenax Therapeutics
TENX
$64.4M
| $24.7M | 0.37% |
1,700,000
+252,218
| +17% | +$3.22M |
2025 Q4
2 quarters
|
|
55
CALL
Capricor Therapeutics
CAPR
$354M
| $24.1M | 0.36% |
+1,000,000
| New | +$30.3M |
2026 Q2
0 quarters
|
|
56
PUT
SELLAS Life Sciences
SLS
$2.46B
| $22.1M | 0.33% |
+1,500,000
| New | +$10.4M |
2026 Q2
0 quarters
|
|
57
Nautilus Biotechnolgy
NAUT
$364M
| $21.8M | 0.33% |
11,634,211
-960,000
| -8% | -$2.53M |
2021 Q2
20 quarters
|
|
58
Orchestra BioMed
OBIO
$347M
| $21.7M | 0.33% |
5,037,906
| – | – |
2023 Q1
13 quarters
|
|
59
Intuitive Surgical
ISRG
$158B
| $20.6M | 0.31% |
51,884
-33,535
| -39% | -$14.7M |
2023 Q4
10 quarters
|
|
60
Adlai Nortye Group ADS
ANL
$695M
| $20.6M | 0.31% |
+1,793,190
| New | +$21.8M |
2026 Q2
0 quarters
|
|
61
Contineum Therapeutics
CTNM
$339M
| $20.6M | 0.31% |
1,255,592
| – | – |
2024 Q2
8 quarters
|
|
62
Nuvectis Pharma
NVCT
$602M
| $18.4M | 0.28% |
+1,000,000
| New | +$11.2M |
2026 Q2
0 quarters
|
|
63
Palisade Bio
PALI
$209M
| $17.6M | 0.26% |
8,425,065
-503,084
| -6% | -$990K |
2025 Q4
2 quarters
|
|
64
Omada Health Inc
OMDA
$1.16B
| $17.3M | 0.26% |
786,330
| – | – |
2025 Q2
4 quarters
|
|
65
LeonaBio Inc
LONA
$46.1M
| $17.1M | 0.26% |
1,859,322
| – | – |
2020 Q3
23 quarters
|
|
66
Evolus
EOLS
$487M
| $17.1M | 0.26% |
2,459,285
+1,172,423
| +91% | +$6.92M |
2026 Q1
1 quarter
|
|
67
PUT
NewAmsterdam Pharma
NAMS
$2.45B
| $16.9M | 0.25% |
+500,000
| New | +$16.5M |
2026 Q2
0 quarters
|
|
68
Invivyd
IVVD
$174M
| $16.1M | 0.24% |
18,490,636
-2,368,667
| -11% | -$2.97M |
2025 Q4
2 quarters
|
|
69
Mirum Pharmaceuticals
MIRM
$5.56B
| $13.5M | 0.2% |
+115,391
| New | +$11.6M |
2026 Q2
0 quarters
|
|
70
Surrozen
SRZN
$346M
| $13.1M | 0.2% |
503,985
+274,592
| +120% | +$7.54M |
2026 Q1
1 quarter
|
|
71
Beta Bionics
BBNX
$1.16B
| $13.1M | 0.2% |
832,944
-10,000
| -1% | -$119K |
2025 Q1
5 quarters
|
|
|
72
PUT
Capricor Therapeutics
CAPR
$354M
| $12M | 0.18% |
+500,000
| New | +$15.2M |
2026 Q2
0 quarters
|
|
73
Axogen
AXGN
$2.19B
| $11.4M | 0.17% |
247,312
-450,000
| -65% | -$18.1M |
2025 Q4
2 quarters
|
|
74
Oscar Health
OSCR
$9.7B
| $11.4M | 0.17% |
+400,000
| New | +$8.61M |
2026 Q2
0 quarters
|
|
75
Oculis Holding
OCS
$481M
| $11.2M | 0.17% |
808,827
+315,000
| +64% | +$7.15M |
2025 Q4
2 quarters
|
|
Similar funds
Perceptive Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Perceptive Advisors held 121 positions worth $6.66B, up 30% from $5.12B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $235M of net new capital in Q2 2026, opening 27 new positions and adding to 30 existing holdings. Its largest new stake was Kardigan Inc: 8,200,662 shares worth $196M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $85.9M trimmed.
- Perceptive Advisors's largest Q2 2026 buy was Kardigan Inc: 8,200,662 shares worth $196M.
- Perceptive Advisors added most to Tango Therapeutics in Q2 2026, an estimated $63.5M increase.
- Perceptive Advisors's biggest Q2 2026 reduction was Ascendis Pharma A/S, cutting an estimated $85.9M.
- Perceptive Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $209M.
- Perceptive Advisors's ten largest holdings make up 47% of its $6.66B portfolio in Q2 2026.
- Perceptive Advisors opened 27 new positions and closed 12 in Q2 2026.
- Perceptive Advisors's portfolio value rose 30% quarter-over-quarter to $6.66B.
Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.